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The Abelson murine leukemia virus transforming gene product is a phospho-
rylated protein encoded by both viral and cellular sequences. This gene product
has an amino-terminal region derived from the gag gene of its parent virus and
a carboxyl-terminal region (abl) derived from a normal murine cellular gene.
Using a combination of partial proteolytic cleavage techniques and antisera
specific for gag and abl sequences, we mapped in vivo phosphorylation sites to
different regions of the protein. Phosphoproteins encoded by strain variants and
transformation-defective mutants of Abelson murine leukemia virus with defined
deletions in the primary sequence of the abl region were compared by two-
dimensional limit digest peptide mapping. Specific phosphorylation pattern dif-
ferences for wild-type and mutant proteins probably represented deletions of
specific phosphate acceptor sites in the abl region. An in vitro autophosphoryla-
tion activity copurified with the Abelson murine leukemia virus protein from
transformation-competent strains. A peptide analysis of such in vitro reactions
demonstrated that these phosphorylation sites were restricted to the amino-
terminal region, and the specific sites appeared to be unrelated to the sites found
on proteins phosphorylated in vivo. Thus, the autophosphorylation reaction
probably correlates with an activity important in transformation, but the specific
end product in vitro bears little resemblance to its function in vivo.
Abelson murine leukemia virus (A-MuLV) is
a member of an increasingly large group of rep-
lication-defective rapidly transforming retrovi-
ruses (9, 27). Derived from the replication-com-
petent Moloney murine leukemia virus by re-
combination with a normal cellular gene, A-
MuLV expresses transforming activity for both
established fibroblast lines in vitro and pre-B
cells in vitro and in vivo (1, 2, 17-19, 24). A-
MuLV retains homology to Moloney murine
leukemia virus at the ends of its genome but
contains sequences derived from a cellular gene
intemally (7, 15, 26, 31, 32). These internal se-
quences are referred to as the abl region. The
nucleic acid recombination in A-MuLV results
in the production of a fused protein containing
an amino-terminal region precisely homologous
to Moloney murine leukemia virus gag gene
subregions p15 and p12 and a portion of p30 and
a carboxyl-terminal region derived from the ac-
quired cellular sequences. An auto-phosphoryl-
ation activity specific for tyrosine residues co-
purifies with the A-MuLV protein (28). No other
A-MuLV-specific primary translation product
has been identified. Deletion and premature ter-
mination mutants in the carboxyl-terminal abl
region which show parallel changes in trans-
forming potential and the level of the in vitro
phosphotyrosine kinase activity (20, 21, 23, 29)
strongly suggest that this protein contains the
transforming function for A-MuLV.
The A-MuLV protein is a phosphoprotein in
vivo (16, 32). Defining the role of the cellular
protein kinases or the auto-phosphorylation ac-
tivity of the A-MuLV protein in these in vivo
post-translational modifications could aid in our
understanding of the control of the function of
this protein. In this study we began such an
analysis by identifying the regions and specific
sites on the A-MuLV protein which are phos-
phorylated, as well as the specific differences
expressed by mutant strains of A-MuLV.
MATERIALS AND METHODS
Cells and viruses. Each strain of A-MuLV was
isolated in a transformed nonproducer clone of NIH/
3T3 cells (20, 21, 24).
Labeling and immunoprecipitation. The tech-
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niques used for metabolic labeling with [5S]methio-
nine, in vitro auto-phosphorylation with [y-3nP]ATP,
and in vivo labeling with 'Pi have been described
previously (20, 28, 32). The methods used for immu-
noprecipitation of detergent-lysed cellular extracts
with gag gene-reactive antiserum (goat anti-Moloney
virions, rabbit anti-p15, and goat anti-p12) and abi-
specific anti-Abelson tumor serum (anti-AbT) have
also been described previously (11, 30, 32). Samples
were analyzed by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis and fluorography (3,
13).
Partial proteolytic one-dimensional peptide
mapping. A modification of the method of Cleveland
et al. (4, 34) was used. Samples isolated by immuno-
precipitation with a standardized amount of each spe-
cific antiserum were recovered from the Staphylococ-
cus aureus immunoadsorbant in a solution containing
1% SDS, 1% 2-mercaptoethanol, and 50 mM Tris (pH
6.8). A portion of each sample (usually 10 p1) was
mixed with an equal volume of enzyme solution in 50
mM Tris (pH 6.8) and then incubated at 370C (for
times, see below). The reaction was termi9ated by
adding an equal volume of 2% SDS-2% 2-mercapto-
ethanol and heating at 700C for 5 to 10 min. Digested
or control preparations were analyzed directly by
SDS-polyacrylamide gel electrophoresis. Alterna-
tively, preparations were diluted into immunoprecipi-
tation detergent lysis buffer, and fragments were im-
munoprecipitated with antisera specific for regions of
the A-MuLV protein.
Two-dimensional peptide mapping. Different
A-MuLV proteins labeled with 32P from in vitro kinase
reactions or in vivo labeling were isolated by immu-
noprecipitation and gel electrophoresis, visualized by
autoradiography, and excised from dried gels. Gel
pieces were processed and limit digested with a-chy-
motrypsin as previously described (5). Samples were
electrophoresed in the first dimension on thin-layer
cellulose sheets in formic acid-acetic acid-water (5:15:
80) and then chromatographed in the second dimen-
sion by ascending chromatography in acetic acid-pyr-
idine-butanol-water (5:25:32.5:20) containing 7.2%
PPO (2,5-diphenyloxazole; Eastman Chemicals), as
previously described (5, 6).
RESULTS
Summary of A-MuLV strains. Table 1
shows summary of the genome structures, trans-
forming activities, and relative in vitro tyrosine
auto-phosphorylation activities of the A-MuLV
strains used in this study. Each A-MuLV protein
and virus strain is referred to by the size of the
protein in kilodaltons, as estimated by SDS-
polyacrylamide gel electrophoresis.
The relative genome structures deduced from
Southern blot analyses (7, 8) demonstrated that
the strain P160 genome (6.3 kilobases) contained
a region of 800 bases in the abl-specific region
that was not found in strain P120 or the other
strains. The genomes of strains P120, P100, P90,
and P85 were the same size (5.5 kilobases), and
the smaller primary translation products of
these strains were probably due to premature
stop codons caused by single base changes or
very small deletions. Strain P92 was a true trans-
formation-defective mutant. Its genome had an
additional deletion of 700 bases in the center of
the abl sequences, which resulted in a total loss
of transforming activity for fibroblasts and
lymphoid cells and a loss of in vitro kinase
activity (29).
All strains appeared to have identical Molo-
ney murine leukemia virus-derived gag gene
sequences at the 5' ends of their genomes and to
share extensive regions of the abl sequences.
These observations were supported by immu-
noprecipitation analyses in which we used rabbit
monospecific antisera against thegag gene prod-
ucts p15, p12, and p30 and a tumor regressor
serum (anti-AbT) specific for the abl-encoded
region (20, 21, 30).
Limited proteolysis of A-MuLV proteins.
From the nucleic acid structures of the different
A-MuLV strains, we predicted a common amino-
terminal region of about 50,000 daltons for all of
the A-MuLV proteins (comprised of gag gene
and some abl gene sequences) and carboxy-ter-
minal regions of varying lengths and composi-
tions (derived entirely from abl sequences).
We used partial proteolytic cleavage (Fig. 1)
in the presence of SDS and an analysis of the
resulting fragments by gel electrophoresis as de-
scribed by Cleveland et al. (4, 34) to compare
proteins with homologous regions as well as
unique sequence regions. To begin such an anal-
ysis, we suspended [3S]methionine-labeled P90
(Fig. 1, lanes A), P120 (lanes B), and P160 (lanes
C) proteins isolated from transformed nonpro-
TABLE 1. Summary ofA-MuLV strains
Comabn re- Transformation activity
plete rion
Straina genome siz(kilo- (kilo- Fibro- Lymph- In vitro(kilo- bases) blast oid kinasebases)
P160 6.3 4.3 +++ +++ +++
p120b 5.5 3.5 +++ +++ +++
Pl00c 5.5 3.5 +++ + +
P9CC 5.5 3.5 +++ + +
P85c 5.5 3.5 +++ + +
P92d 4.8 2.8 - - -
a Each strain of A-MuLV was named for the size of
its encoded protein in kilodaltons.b Strain P120 was derived by deletion of 800 bases
from the center of the abi sequences in strain P160.
cStrains P100, P90, and P85 were derived from
strain P120 and probably represented chain termina-
tion mutants caused by point mutations or small dele-
tions.
d Strain P92 was derived from strain P120 by a 700-
base deletion from the abi sequences.
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FIG. 1. Partial proteolytic cleavage ofA-MuLV proteins. (a and b) Transformed nonproducer fibroblast
clones of strains P90 (lanes A), P120 (lanes B), and P160 (lanes C) were labeled for 2 h with [36S]methionine
(100 ,uCi/5 x 106 cells), extracted, clarified, and immunoprecipitated with goat anti-Moloney virion antiserum
(32). (a) A portion of each preparation was denatured, electrophoresed on a 10% polyacrylamide gel, and
developed by fluorography (3, 13). (b) Equivalent portions (representing 2.0 1l of goat antiserum) were
denatured in SDS gel sample buffer (10 I), diluted with 10 ,Ll of S. aureus V8 protease (10 ,ug/ml) in 50 mM
Tris (pH 6.8), and reacted at 37°C for 30 min. The reactions were terminated by adding 10 ,tl of twofold-
concentrated gel sample buffer and heating at 70°C for 10 min; the resultingpreparations were then analyzed
as described above. (c and d) Equal numbers of unlabeled cells were extracted, clarified, and immunoprecip-
itated as described above; then, the A-MuLVproteins were labeled with [y-32P]ATP by the auto-phosphoryl-
ation reaction (28). Samples were treated as described above for control (c) and protease-digested (d)
comparisons. The positions ofprotein molecular weight markers, including bovine serum albumin (molecular
weight, 68,000 [68K]), heavy-chain immunoglobulin (50,000), and light-chain immunoglobulin (25,000), are
also shown.
ducer NIH/3T3 fibroblast clones by immuno-
precipitation in 0.5% SDS buffer and subjected
them to control conditions (Fig. la) or to diges-
tion with S. aureus V8 protease (Fig. lb). These
preparations (Fig. la) contained small amounts
of a common, naturally occurring fragment of
80,000 daltons, as well as the expected initial
90,000-, 120,000-, and 160,000-dalton proteins of
the different A-MuLV strains. Each cleaved
preparation (Fig. lb) contained some residual
starting material and a distinctive cleavage frag-
ment, which varied in size from 45,000 daltons
(Fig. lb, lane A) to 75,000 daltons (lane B) to
115,000 daltons (lane C). These cleavage frag-
ments would have been expected if a major site
about 45,000 daltons from the amino terminus
of each protein had been cleaved, generating a
common amino-terminal fragment and different
carboxyl-terminal fragments from the different
A-MuLV strains. Longer exposures of such
cleavage patterns of [3S]methionine-labeled A-
MuLV proteins did show the predicted common
45,000-dalton fragment. This amino-terminal re-
gion was relatively methionine poor and was
documented better with other labeling tech-
niques.
The same A-MuLV proteins (P90, P120, and
P160) were isolated by immunoprecipitation, la-
beled in vitro with [-y-32P]ATP by the tyrosine
auto-phosphorylation reaction (28), and sub-
jected to the same digestion protocol (Fig. lc
and d). All three strains showed as major cleav-
age products a set of fragments of about 45,000
daltons, which could have represented the pre-
dicted common amino-terminal region. Time
course or dose-response digestion studies
showed that the uppermost bands in the 45,000-
dalton region appeared first and were probably
then cleaved to yield the slightly smaller frag-
ments in the group (see below). Thus, the ma-
jority of the [y-32P]ATP label appeared to be
localized in a region common to all three strains.
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Interestingly, we found a very similar pattern
of fragments for methionine- and ATP-labeled
proteins by using proteases having quite differ-
ent specificities, such as chymotrypsin, thernol-
ysin, and pronase. This suggested that a partic-
ularly protease-sensitive region was exposed
preferentially even under the SDS denaturing
conditions used in these studies. Similar results
were obtained with strains P100 and P85 (data
not shown).
To document the origin of these specific frag-
ments further, we oriented them by using anti-
sera specific for certain subregions of the gag
gene (specifically, the p15 and p12 proteins) and
antiserum specific for the abl sequences (Fig. 2).
Protein P120 was labeled by the in vitro auto-
phosphorylation reaction with [y-32P]ATP and
then subjected to control conditions (Fig. 2,
lanes A) or to digestion with increasing amounts
of S. aureus V8 protease (lanes B through D).
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FIG. 2. Localization of the in vitro kinase phos-
phate acceptor sites near the amino terminus. Prep-
arations of strain P120 protein labeled with [y-32P
ATP by the tyrosine auto-phosphorylation reaction
were prepared as described in the legend to Fig. 1.
Samples were reacted for 30 mn in control buffer
(lanes A) or with S. aureus V8 protease at 1 tg/ml
(lanes B), 3 pg/ml (lanes C) or 10gL,gml (lanes D);
subsequently, these preparations were heat inacti-
vated at 700*C for 5 min and diluted into immunopre-
cipitation buffer. Portions were re-immunoprecipi-
tated and analyzed by gel electrophoresis. (a) Normnal
rabbit serum. (b) Rabbit anti-p15 serum. (c) Normal
mouse serum. (d) Mouse anti-AbT absorbed to react
specifically with the abl sequences of P120 only (30).
68K, 68,000 daltons.
The cleavage reactions were stopped by heating,
and then portions of the preparations were di-
luted and immunoprecipitated as described
above with normal rabbit serum (Fig. 2a), rabbit
anti-p15 (the most amino-terminal portion of
the gag gene and P120) (Fig. 2b), normal mouse
serum (Fig. 2c), and mouse anti-AbT (specific
for the abl-derived portion of P120) (Fig. 2d).
Even after heating in SDS, enough antigenic
structure was retained so that labeled protein
P120 and protein fragments could be recognized
by the specific antibodies. The 45,000-dalton set
of fragments labeled by the auto-phosphoryla-
tion reaction appeared to represent a common
amino-terminal region which contained the gag
sequence and a portion of the abl sequences.
Similar studies with anti-p12 antiserum gave the
same results (see below). Additional control im-
munoprecipitations with anti-plO antiserum
(plO was a portion of the gag gene not found in
A-MuLV proteins) were negative (data not
shown). Such immunoprecipitation studies
could not prove that the precise amino terminus
was present in the 45,000-dalton fragment since
small cleavages near the end could have left
enough of the p15 sequence intact to be recog-
nized for immunoprecipitation. Some indirect
support for the presence of the precise amino
terminus in this fragment came from the fact
that protein P120 labeled with [3H]acetate gave
rise to a labeled 45,000-dalton fragment (but not
the 75,000-dalton fragment) after cleavage with
S. aureus V8 (data not shown). The amino ter-
minus of the gag gene protein p15 is known to
be blocked by acetylation (14) and should mark
this end of the protein P120 molecule as well.
Conversion of the label to forms other than the
expected acetate group could not be ruled out.
Figure 3 shows the orientations of the car-
boxyl-terminal fragments of 45,000 daltons for
strain P90, 75,000 daltons for strain P120, and
115,000 daltons for strain P160. [35S]methionine-
labeled proteins were subjected to control con-
ditions (Fig. 3a) or to cleavage with S. aureus
V8 protease (Fig. 3b), and the total products
were analyzed by gel electrophoresis. Portions
of control digestions (Fig. 3c) and S. aureus V8-
cleaved preparations (Fig. 3d) were diluted and
immunoprecipitated with anti-AbT. The car-
boxyl-terminal fragments of 45,000 daltons
(lanes A), 75,000 daltons (lanes B), and 115,000
daltons (lanes C) were recovered with anti-AbT
(Fig. 3d). An additional fragment of about 60,000
daltons was found only in digests of strain P160
(Fig. 3d, lane C) and was precipitated with anti-
AbT. The precise location of this fragment
within the abl region was not identified further.
Control sera, including normal mouse serum,
normal rabbit serum, and rabbit anti-gag gene
VOL. 39, 1981
874 WITTE ET AL.
a
A BC
I ,ci
b
A B C
-P160-
OR P120-
* P90-
* -68K-
*; 9-50K,
7: -25K--
FIG. 3. Variation in the abl-specific regions of dif-
ferent A-MuLV strains. [35S]methionine-labeled
strain P90 (lanes A), P120 (lanes B), and P160 (lanes
C) proteins were prepared and isolated by immuno-
precipitation as described in the legend to Fig. 1.
Samples from controlpreparations (a) or V8-digested
preparations (10 pg/ml; 30 min; 37°C) (b) were ana-
lyzed on a 10% polyacrylamide gel without further
processing. Samples from control preparations (c)
and digested preparations (d) were diluted and re-
immunoprecipitated with anti-AbT rendered specific
for abl sequences by absorption. 68K, 68,000 daltons.
product serum, did not precipitate any of these
carboxyl-terminal fragments (data not shown).
In vitro and in vivo phosphorylation
sites. To begin a study of phosphorylation sites
(Fig. 4), we compared protein P120 preparations
labeled by in vitro auto-phosphorylation (Fig.
4A and B) and labeled in vivo with 32Pi (Fig. 4C
and D). Each preparation was subjected to con-
trol incubation (lanes 1) or to digestion with
increasing amounts of S. aureus V8 protease
(lanes 2 and 3) and then diluted and immuno-
precipitated with anti-p12 serum (Fig. 4A and
C) or anti-AbT (Fig. 4B and D). Most striking
were the similar patterns obtained with the two
labeled preparations. The predominant frag-
ments in both in vitro- and in vivo-labeled prep-
arations included the amino-terminal 45,000-dal-
ton bands which reacted with anti-p12 serum
and anti-AbT and a series of smaller fragments
(about 15,000 to 20,000 daltons), which were
reactive only with anti-p12 serum (Fig. 4A, lane
3, and Fig. 4C, lane 3). These small fragments
were not precipitable with anti-p15 serum (data
not shown). A small amount of the 75,000-dalton
fragment from the carboxyl-terminal (abl) re-
gion was recovered with anti-AbT from the in
vivo-labeled preparation only (Fig. 4D, lane 2).
The 75,000-dalton fragment was not recovered
from any of the in vitro-labeled preparations.
This 75,000-dalton fragment was more sensitive
to further proteolysis.
The abl-specific carboxyl-terminal fragments
(75,000-dalton fragment from protein P120 and
115,000- and 60,000-dalton fragments from pro-
tein P160) could be recovered in higher yields
by using a lower ratio of protease to substrate or
by following the kinetics of digestion (Fig. 5).
This was true when 32Pi-labeled P120 (Fig. 5A)
or P160 (Fig. 5B) was digested under control
conditions (lanes 1) or with 1, 2, or 4 ,ug of S.
aureus V8 protease per ml (lanes 2 through 4,
respectively) for 20 min.
Although the partial protease digests showed
extensive apparent homologies between the in
vitro and in vivo phosphate-labeled preparations
of protein P120, a detailed comparison by two-
diinensional peptide mapping gave a very differ-
ent picture (Fig. 6). Protein P120 labeled in vivo
(panel A) with 32Pi or in vitro with [-y-32P]ATP
(panel B) was limit digested with a-chymotryp-
sin, and the peptides were analyzed by thin-layer
electrophoresis and chromatography. Most
striking was the fact that very few (if any) of the
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FIG. 4. Partial protease maps of in vitro- and in
vivo-phosphorylated P120. Strain P120 protein iso-
lated by immunoprecipitation and labeled by the in
vitro auto-phosphorylation reaction (A and B) was
prepared as described in the legend to Fig. 1. In vivo-
phosphorylated P120 was isolated by immunoprecip-
itation from cells labeled with 32Pi (C and D) (2 mCi/
5 x 106 cells; 4 h at 37°C in phosphate-free medium
containing 10% dialyzed calf serum). Samples from
control reactions (lanes 1) or from 3-pg/ml digests
(lanes 2) or 10-,g/ml digests (lanes 3) were heat
inactivated, re-immunoprecipitated with goat anti-
p12 (A and C) or mouse anti-AbT specific for abl
sequences (B and D), and analyzed as described
above. The positions of the important 75,000-dalton
(F75) and 45,000-dalton (F45) cleavage fragments are
also shown.
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ial migrated some of these were labeled on serine, and some
abeled pep- were labeled on tyrosine (25, 28; unpublished
included at data). Very similar observations were made by
which were Reynolds et al. (16) and Sefton et al. (25), who
iere were at also noted the lack of common sites for in vivo-
any did not and in vitro-labeled P120. Thus, although the
atography); regional localization was similar for a portion of
the phosphates on in vitro- and in vivo-labeled
P120, the specific sites were distinct. Two-di-
mensional peptide maps of in vitro-labeled pro-
tein P160 and P90 preparations were indistin-
guishable from the map of protein P120 (data
not shown). However, when protein P92 (the
P i 60 kinase-negative protein) was labeled in a trans
!F I 5 assay by co-immunoprecipitation with protein
P120 (33) before the in vitro kinase reaction was
carried out, the pattern was different. The pep-
tides labeled in protein P92 represented a subset
- F60 of those labeled in protein P120. The sites reac-
tive in the trans kinase assay represented only
a portion of the sites labeled in the auto-phos-
-_ F4 5 phorylation reaction (data not shown).
Mutant strains lose specific in vivo phos-
phorylation sites. Although the in vitro ki-
nase-labeled two-dimensional peptide maps of
the different A-MuLV strains were very similar,
the in vivo phosphate-labeled maps were distinct
de fragments. (Fig. 7). Only some spots well separated from(B) proteins the base line were numbered. Strain P120 con-
sbjected to tained four distinct peptides (peptides 1 throughge8ted for 2 4). Strain P90, which lacked the carboxyl-ter-ge at 1 pg/mi
,ml (lanes 4). minal 30,000 daltons of strain P120, lacked pep-
lyacrylamide tide 2. Strain P92, which had an intemal deletion
15, Fragment in the abl sequences of strain P120, lacked pep-
tide 4 but retained peptides 1, 2, and 3. Strain
FIG. 6. Two-dimensional peptide maps of in vitro- and in vivo-phosphorylated P120. Strain P120 protein
labeled by the in vitro auto-phosphorylation reaction (B) or labeled in vivo with 32p, (A) was isolated by
immunoprecipitation and gel electrophoresis. Labeled peptide was limit digested from gel slices with a-
chymotrypsin, concentrated by lyophilization, and then analyzed on cellulose thin-layer plates. Electropho-
resis was from right to left at 1 kV for 1 h in formic acid-acetic acid-water (5:15:80). Plates were dried and
chromatographed in an ascending buffer containing pyridine, butanol, acetic acid, and water (25:32.5:5:20)
from bottom to top. Plates were autoradiographed with intensifying screens to shorten exposure times.
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FIG. 7. A-MuLV strain variants lose specific in vivo phosphorylation sites. 32Pi in vivo-labeled strain P92
(A), P90 (B), P120 (C), and P160 (D) proteins were isolated by immunoprecipitation, digested, and analyzed as
described in the legend to Fig. 6.
P160, which contained an additional sequence in
the abl region, lacked peptide 1, but a new
peptide (peptide 5) was resolved. Shorter expo-
sures, which resolved additional peptides clus-
tered along the base line, did not show any useful
differences among the various strains (data not
shown). It was not possible to assign these phos-
phorylation differences definitively to specific
deletions or insertions in the primary sequence
since a conformational change induced from one
change could have influenced the rate or stabil-
ity of phosphorylation at a distant site. The
presence of multiple phosphorylation sites in the
strain P92 protein suggested that cellular en-
zymes may be responsible for most, if not all, of
the phosphates added to A-MuLV-encoded pro-
teins in vivo.
DISCUSSION
The results of one- and two-dimensional pep-
tide mapping studies of the various A-MuLV
proteins are in good agreement with the struc-
tures predicted by nucleic acid analyses (7, 8).
The A-MuLV proteins contained a common
amino-terminal segment of about 40,000 to
45,000 daltons and carboxyl-terminal regions of
varying lengths and compositions.
Clearly, deletion and premature termination
variants of A-MuLV proteins have altered in
vivo phosphorylation patterns, but the roles of
cellular enzymes and varying auto-phosphoryl-
ations have not been determined. It is surprising
how much primary sequence can be deleted from
the largest A-MuLV protein (P160) to the small-
est A-MuLV protein (P85) with the protein still
retaining some transforming activity. We sus-
pect that such nonessential regions may play a
regulatory role in the biology of the normal
cellular gene product ofthe abl locus, designated
NCP150 (31). The presence of multiple phos-
phorylation sites in the abl sequences and the
deletion of specific sites in well-studied deletion
and termination mutants may be useful in elu-
cidating such control regions.
The transformation-defective, in vitro kinase-
negative mutant P92 lacked only a single major
phosphorylation site in vivo (Fig. 7, peptide 4).
We suspect that cellular enzymes are responsible
for the majority of the phosphorylations in vivo,
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although it is possible that strain P92 may carry
out some auto-phosphorylation in vivo. The
number and possible functions of the cellular
kinases that recognize the abl-specific sequences
remain unknown.
The in vitro tyrosine-specific auto-phospho-
rylation activity labels within the amino-termi-
nal region from 40,000 to 45,000 daltons, and a
number of sites can be utilized. It is not known
whether all of these sites fall within the gag
region. More extensive digestions of the 45,000-
dalton amino-terminal piece do generate smaller
labeled fragments that immunoprecipitate with
anti-gag protein sera but not with anti-AbT
(Fig. 4). This suggests that some of these sites
are within the gag region, but we cannot rule
out the possibility of some labeling in the abl
sequences. The specific peptides labeled bear
little resemblance to the peptides in in vivo
phosphate-labeled preparations (Fig. 6). It
seems likely that the in vitro kinase activity
measured in immunoprecipitates or on partially
purified protein P120 (28) represents an activity
important in vivo but not the precise reaction
found within cells. Deciphering the role of the
A-MuLV kinase activity in vivo has been ap-
proached by several groups. Hunter (10) and
Sefton and co-workers (25) have demonstrated
an elevated phosphotyrosine level in A-MuLV-
transformed cells. This global effect is correlated
with A-MuLV transformation, but defining
which cellular substrates are specifically phos-
phorylated by the A-MuLV kinase will require
further study. Recently, Dasgupta et al. (A. Das-
gupta, D. Baltimore, M. Spector, R. Pepinski, V.
Vogt, and E. Racker, manuscript in preparation)
have shown that partially purified preparations
of A-MuLV P120 can specifically phosphorylate
in vitro a purified regulatory protein (designated
PKS) involved in the cascade-like control of cell
membrane ATPase activity (M. Spector, S.
O'Neal, and E. Racker, J. Biol. Chem., in press).
Whether this specific reaction can account for
the function of the A-MuLV transforming pro-
tein in vivo is not known, but it provides a model
system for further analysis.
Although the roles of specific in vivo phospho-
rylation sites on the A-MuLV protein itself are
not known, the possibility that cellular protein
kinases may modulate A-MuLV kinase activity
needs further investigation (12, 22).
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